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Abstract
During an ischemic event, the well-regulated  glutamate (Glu) homeostasis is disturbed, which gives rise to
extremely  high levels of this excitatory  neurotransmitter  in the brain tissues. It was earlier reported that the
administration of oxaloacetate (OxAc) as a Glu scavenger reduces the Glu level in the brain by enhancing the
brain-to-blood Glu efflux. Here, we studied the neuroprotective effect of OxAc administration in a new focal
ischemic model in rats. Occlusion  of the middle cerebral artery  resulted in immediate reduction of the
somatosensory evoked responses (SERs), and the amplitudes remained at the reduced level throughout the whole
ischemic period. On reperfusion, the SERs started to increase, but never reached the control level. OxAc proved
to be protective, since the amplitudes started to recover even during the ischemia, and finally fully regained the
control level. The findings of the histological measurements were in accordance with the electrophysiological
data. After Fluoro Jade C staining, significantly fewer labeled cells were detected in the OxAc-treated  group
relative to the control. These results provide new evidence of the neuroprotective effect of OxAc against
ischemic injury, which strengthens the likelihood of its future applicability as a novel neuroprotective agent for
the treatment of ischemic stroke patients.
Introduction
Cerebrovascular  diseases, stroke and closed head injuries are prominent among the leading causes of death
worldwide. In the past two decades, the rank of stroke among the top causes of death has not changed. In 2010,
one in four deaths were due to stroke, as compared with one in five in 1990. Thrombolysis is the only possible
neuroprotective solution in the clinic. Glutamate (Glu), the main excitatory neurotransmitter in the brain, which
is released in excess quantity in the course of an ischemic attack, plays a central role in the secondary damage
(Choi, 1988; White et al., 2000; Vesce et al., 2007). Considerable effort has been devoted to reducing the effects
or the level of the excess neurotoxic Glu in the brain. Most of the developed methods proved to be effective in
animal experiments, with outstanding results from the use of NMDA blockers, for instance, but unfortunately
these methods failed in the clinical trials (Ginsberg, 2008). In the past decade, a number of new and promising
approaches have emerged to decrease the harmful consequences of brain ischemia. One of the most promising is
Glu  scavenging,  based  on  the  enhanced  outflow  of  excitotoxic  Glu  from  the  brain  into  the  blood  as  a
consequence of the decreasing blood Glu level (Gottlieb et al., 2003).
The homeostasis of Glu is a well-regulated process in the brain. Glu is present in widely-ranging concentrations
in the different compartments of the brain Glu homeostasis system. Under normal conditions, the Glu level is
maintained at ~1 µ M in the brain interstitial fluid and cerebrospinal fluid. Its levels are much higher in the
neurons (~10 mM) and synaptic vesicles (~100 mM) (O'Kane et al., 1999). During neuronal communication, the
Glu transporters of the nerve teminals and perisynaptic astrocytes are responsible for the removal of Glu from
the synaptic cleft (Danbolt, 2001). Moreover, the Glu uptake from the interstitial fluid is also regulated by the
Na+-dependent excitatory amino acid transporters (EAATs) present on the brain capillary endothelial cells (Beart
and O'Shea, 2007). Under specific physiological and pathological conditions, Glu can pass into the blood stream
via the endothelial cells with the aid of EAATs and facilitative Glu transporters on the luminal side (Teichberg et
al., 2009). This unidirectional transport can be enhanced by decreasing the blood Glu level. Previous studies
have demonstrated the neuroprotective effect of the i.v. administration of the Glu-oxaloacetate transaminase
(GOT) in the disappearance of the high level of Glu in the brain under pathological conditions (Zlotnik et al.,
2007; Zlotnik et al., 2008; Campos et al., 2011a). This blood-resident enzyme catalyses the transformation of
Glu and oxaloacetate (OxAc) to 2-α-ketoglutarate and aspartate. The peripheral application of OxAc, as GOT
cosubstrate can also be used for Glu scavenging. The neuroprotective effect of OxAc has previously been
demonstrated in focal (Nagy et al., 2009; Campos et al., 2011a) and global (Marosi et al., 2009) ischemic
models. We recently described a new focal ischemic model in the rat (Knapp et al., 2013).
The aim of the present work, was to investigate the possible protective effect of the administration of OxAc in
this new focal ischemic model by electrophysiological and histological methods.
Materials and methods
Animals and surgery
Male adult Wistar (Charles River) rats weighing 250-300 g (N = 5 in each group) were used in the experiments.
The animals were given free access to food and water prior to surgery. All procedures  were approved by the
Animal Care  Committee of  the  University and  were  conducted according to  the  recommendations of  the
Declaration  of Helsinki and Tokyo. Every effort was made to minimize animal suffering and to reduce the
number of animals used in this study. Experiments were carried out under Nembutal anesthesia (65 mg/kg and
40 mg/kg/30 min). Body temperature was maintained at 37 ± 0.5 ºC through the use of a self-regulating heating
pad (TMP 5-b, Supertech, Budapest, Hungary) and a rectal probe.  The surgical procedure, the experimental
protocol  applied  including  the  induction  of  focal  ischemia,  the  electrophysiological  recording  and  the
histological procedures were similar to those in our previous study (Knapp et al., 2013). Briefly, craniotomy was
performed over the primary somatosensory cortex, and on the left side the temporal skull was opened for
preparation of the trunk of the middle cerebral artery (MCA). To induce ischemia, the MCA was lifted with a
special micromanipulating hook moved by a micromanipulator. The duration of ischemia was adjusted to 2 x 15
min (interrupted by a 30-min reperfusion). The survival rate was 91% (10/11 animals).
Experimental groups and treatments
OxAc (Sigma–Aldrich, Munich, Germany) or saline was administered into the right tail vein during the first 15-
min ischemic period (volume: 1 ml, duration: 15 min, speed:  66.6 µ l/min) with  the aid of a microinjection
pump (CMA/100, CMA Microdialysis AB, Kista, Sweden). On the basis of previous studies (Nagy et al.,
2010; Campos et al., 2013), the dose of OxAc was 3.5 mg/100 g. OxAc was solved in phosphate buffer; the pH
was set to 7.4.
Electrophysiology
Somatosensory evoked responses (SERs) were induced as described previously (Toldi et al., 1994) and were
recorded (in 5 animals per group) before, during and after the ischemic period (120 min). Briefly, the trigeminal
nerve was stimulated by electrical stimulation of the whisker pad (4 V, 0.2 ms, 0.1 Hz) through a bipolar needle
electrode (Toldi et al., 1994; Farkas et al., 2000). The recordings were made on the surface of the dura with the
aid of a silver electrode. The punctum maximum of the SERs was identified; it was generally localized 3.5 mm
behind the bregma and 5 mm laterally. The amplified responses were processed and averaged with Experimetria
Intrasys software (Experimetria Ltd., Budapest, Hungary). The 30-min control period was followed by 2 x 15-
min ischemic episodes interrupted by a 30-min reperfusion.
Histology
For histological assessment after a 1-day survival period (following surgery), the animals (N = 10) received an
overdose of urethane, and were perfused transcardially with 0.1 M ice-cold phosphate-buffered saline (pH 7.4),
followed by 4% buffered paraformaldehyde.  The brains were removed, and postfixed overnight in
paraformaldehyde at 4 °C. Coronal sections (20 µ m) were obtained from -2.0 to  -6.0 mm behind the bregma
with a vibratome (Leica VT1000 S, Leica Microsystems, Wetzlar, Germany). In this work, every tenth 20-µm
slice was analyzed in the length of 4 mm (Fig. 2A) from the area supplied by the MCA. The early changes in
neural  viability induced by the ischemia and reperfusion were visualized by means of Fluoro Jade C (FJC)
staining. Cortical FJC-positive cells were counted in the quadrant (0.25 mm2) of slices in the same position. The
slices  were mounted on gelatine-coated  slides, then coverslipped with Fluoromount. Fluorescence
photomicrographs  were obtained with an Olympus BX51 microscope  fitted with a DP70 digital imaging
system. Solvents were obtained from Sigma-Aldrich Co (Munich, Germany).
Statistical analysis
Electrophysiology
Repeated measurements of SER amplitudes of the control and OxAc treated groups were compared separately
with the aid of the non-parametric Related-Samples Friedman’s Two-Way Analysis of Variance by Ranks.
Hystology
Numbers of FJC+ cells were compared with the Generalized Linear Mixed Model. During the data analysis
Poisson distribution of the data was considered. The effects of the different rats were used as nested random
effects and the different treatments were used as fixed effects in the mixed effect linear model (IBM SPSS
Statistics version 20). A p-value of 0.05 was considered significant.
Results
Electrophysiology
There was an obvious effect of the focal ischemia on the SERs (Fig. 1). In the control group, the amplitudes of
the SERs decreased immediately at the beginning of the occlusion of the MCA and remained at the reduced level
throughout the ischemic period. At the beginning of reperfusion, the amplitudes started to increase, but never
regained the control level. This result was quite similar to that in our previous work (Knapp et al., 2013). In the
other group, where OxAc was administered during the first ischemic event, the result was significantly different.
The decreased amplitudes began to recover even during the ischemia, and finally reached the control level (Fig.
1). The increase in the SER amplitudes was markedly faster than that in the controls. In the OxAc-treated group,
the recovery of the amplitudes was even faster during the second ischemic event than during the first one. The
increase was already observed within 2 min after the beginning of the ischemic period.
Histology
As a result of the occlusion of the MCA with a 1-day survival period, well-outlined FJC-positive cells emerged
throughout the ipsilateral somatosensory cortices supplied by the MCA. Staining was prominent in the cell
membrane and the cytoplasm (Fig. 2B). The FJC-positive cells were easily counted since the FJC dye did not
penetrate into the damaged brain parenchyma  during the survival period. In the control group, the average
number of labeled cells in the slices on the given rectangle obtained at from -2 to -6 mm from the bregma was
different from those of treated group. The OxAc treatment  proved to be protective against the focal cerebral
ischemia, since it led to fewer labeled cells in the same area. Significant difference was evinced between the
control and the treated groups. The data of cell counts are showed in Box diagrams (Fig. 2C), the median of the
cell numbers was 38 in the control and 6 in the OxAc treated group.
Discussion
Despite an intensive search for different neuroprotective strategies and agents against ischemic brain injury, the
only effective treatment is  thrombolysis (Ginsberg, 2008). From the  early 2000s, attention turned to  Glu
scavenging (Gottlieb et al., 2003). This new trend in the field of neuroprotection had the aim of reducing the
excess Glu after ischemia. The procedure is based on decreasing the blood Glu level, which enhances the brain-
to-blood Glu efflux via the Na+-dependent EAATs and the facilitative Glu transporters present on the abluminal
and luminal sides of the endothelial cells, respectively  (Teichberg et al., 2009). An important factor which
supports this process is the huge number and surface area of the brain capillaries.  The human brain contains
approximately 108 capillaries, which have a surface area of ~12 m2 (Bickel et al., 2001). In the compartment of
the blood-brain barrier, the average distance between a capillary and a neuron is ~8-20 µ m, and it may therefore
be stated that virtually every neuron has its own capillary in the brain (Pawlik et al., 1981).
The blood-resident GOT is the key enzyme that influences the blood Glu level. Like in case of Glu–pyruvate
transaminase (GPT) and pyruvate, GOT converts glu into 2-ketoglutarate in presence of oxaloacetate, serving as
the co-substrate for this reaction. The enzymatic activity of GOT has been reported to be higher than that of GPT
both in rats and in humans (Teichberg, 2011). Boyko et al. (2012) first described the pharmacokinetic and
pharmacodynamic properties of GOT and GPT. They found that these two enzymes are largely distributed in the
central circulation and their interactions with Glu also take place there. The explanation of this phenomenon is
the low permeation of GOT and GPT to the peripheral organs. These enzymes require a several-hour delay
before they can affect the pool of serum Glu. The Glu-lowering property of GOT proved to be more effective in
a higher dose, which is due to the low OxAc level in the blood. They therefore concluded that a noteworthy
neuroprotective effect against ischemia may be achieved through the administration of GOT in a higher dose or
through coadministration of the co-substrate OxAc.
The neurological outcome after stroke has been demonstrated to depend on the blood level of GOT. Campos et
al. (2011b) concluded that GOT itself can act as a protective factor against Glu-mediated  pathophysiological
processes: a high GOT level in the blood resulted in a better neurological outcome relative to that at a low GOT
level. It has also been reported, that migraine patients exhibit a lower blood GOT activity and a higher blood Glu
level than those in healthy  control subjects (Campos et al., 2013). In one interesting study, the long-lasting
neuroprotective effects of  Glu scavengers against brain-implanted gliomas were  described. Chronic OxAc
treatment proved to reduce the proliferation and invasiveness  of the glioma cells, decreasing the size of the
gliomas and prolonging  the survival of rats and mice. The excess Glu in the peritumoral  space of a glioma
enhance its invasiveness. The released Glu kills the neighboring cells, thereby providing an increased space for
the occupancy in the brain (Ruban et al., 2012).
The scavenging reaction detailed above can be achieved through the i.v. administration of OxAc after an
ischemic event. This promising four-carbon molecule, takes part in many metabolic and energy-producing
pathways in the body (e.g. the citric acid cycle, gluconeogenesis and the urea cycle). It is well known that, as a
component of the citric acid cycle, OxAc plays a pivotal role in ATP production (Campos et al., 2012).
Numerous studies have described the neuroprotective effect of OxAc. It is protective as a Glu scavenger against
focal cerebral ischemia (Campos et al., 2011a) or global hypoperfusion (Marosi et al., 2009), and also as an
antioxidant against excitotoxic damage (Yamamoto and Mohanan, 2003).
The present study revealed the effects of Glu scavenging  on the cortical evoked potentials in our newly-
developed focal ischemia model. In the control group, the SER amplitudes decreased during the ischemic event,
and were not fully restored after it, reaching ~60% of the control level. As a result of the i.v. injection of OxAc,
the reduced amplitudes started to increase even during the ischemic period and finally regained the control level.
This indicates the rapid changes caused by Glu scavenging. The cortical function maintained its state following
the ischemia. After a 1-day survival period, a marked difference was detected between the two groups on the use
of FJC dye. In the treated group, significantly fewer FJC-positive neurons were counted than in the controls.
In these experiments our aim was to investigate the effect of OxAc treatment in our model. Therefore, in order
to  reach the most remarkable effectiveness, the treatment was performed during the ischemic period.
Nevertheless, in the clinical trials the neuroprotective effect of Glu scavenging also can be achieved during the
hours of occuring Glu excitotoxicity. Our results clearly demonstrate the  neuroprotective effect of OxAc
as a   Glu  scavenger, and the value of this ischemic model for the investigation  of different neuroactive
pharmacological agents.
Several promising studies have suggesed the advantageous effects of Glu scavengers, and especially OxAc. The
most beneficial properties of this molecule are that its effects are not mediated through receptor modulation,
while the process is self-contolled (Teichberg et al., 2009) and occurs naturally in the human body, so that OxAc
can be administered without serious side-effects. Our results additionally  provide new evidence of the
neuroprotective  effect of OxAc, which strengthens the view that it may potentially be applied as a novel
neuroprotective agent for the treatment of ischemic stroke patients in the future.
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Legends to figures
Fig. 1. Changes in SER amplitudes during the short-lasting (15-min) ischemic periods. In the control group 
(■) saline was injected intravenously during the first ischemic event. The maximum amplitudes in both 
reperfusion periods were significantly lower than those in the control period (see the labeled data range). For 
the statistical analysis non-parametric Related-Samples Friedman’s Two-Way Analysis of Variance by Ranks 
model
was used. (*** p < 0.001; Chi-Square: 81,61; df: 2; N = 5, SER amplitudes are expressed as the mean ± 
S.E.M.) In the treated group (○), 3.5 mg/100 g OxAc was administered analogously to the saline 
treatment of the controls. The ischemia-reduced amplitudes finally resumed the control level, the last 10 
min of the reperfusion periods showed no significant (n.s.) difference from the control period. (p=0,592; 
Chi-Square:
1,05; df: 2; N = 5; mean ± S.E.M.)
Fig. 2. Histological studies. (A) Illustration of the location of the analyzed sections (parallel lines) between 
-2 and -6 mm behind the bregma (Br.). The filled black circle indicates the position of electrophysiological 
recording. (B) Representative photomicrograph of the FJC labeling after a 1-day survival. The insert shows 
FJCpositive cells at higher magnification. (C) Box-diagrams of the count of FJC-positive cell in 0.25 mm2 
quadrants of the cortex. Significant difference was detected between the groups with the aid of
Generalized Linear Mixed Model. (** p < 0.01; F: 21,18; df: 1; medians: 38; 6)
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